HBM Partners is a Swiss healthcare investment firm founded in 2001 with USD 2.1 billion in assets under management. The firm focuses on venture, growth, and buy-out financings of private companies, as well as investments in public companies within the biopharma, medtech, diagnostics, and healthcare sectors. Their investment approach spans across Europe, North America, India, China, and other emerging markets. HBM Partners operates under the regulation of FINMA and advises SIX-listed HBM Healthcare Investments Ltd, along with several specialized public and private equity investment funds. They have a track record of over 100 investments, resulting in more than 60 trade sales and IPOs. They aim to be a trusted source of capital for entrepreneurial biopharma and healthcare companies. The firm's team of experienced professionals sources, analyzes, and actively engages in private and public healthcare investments. They support the growth of their portfolio companies through all stages of development, leveraging their experience and global industry network to add value. Their approach is centered on supporting outstanding entrepreneurs and building exceptional companies through innovative ventures.
Bevorzugte Reifephase für die erste Finanzierung.
Biopharma, Medtech, Diagnostics, Healthcare
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
